Autoimmune Disease Treatment Market Research Report- Forecast to 2027

Autoimmune Disease Treatment Market Trends, Size and Industry Outlook By Disease Type (Localized, Systemic), Diagnosis (Elisa, Dot Blot, Agglutination, Others), Therapeutic Products (Drugs, Monitoring Equipment), Distribution Channel – Global Forecast Till 2027

ID: MRFR/Pharma/4137-HCR | February 2021 | Region: Global | 85 pages         

Autoimmune Disease Treatment Market

It is estimated that the autoimmune disease treatment market is expected to grow at a CAGR 4.6% during the forecast period of 2022-2030

Segmentation

By Disease Type Localized Systemic
By Diagnosis Elisa Dot Blot Agglutination
By Therapeutic Products Drugs Monitoring Equipment

Key Players

  • Abbott Laboratories
  • Amgen Inc.
  • Genentech Inc.
  • Bayer Schering Pharma AG
  • Biogen Idec Inc.
  • Bio-Rad
  • Chugai Pharmaceutical Co. Ltd.
  • Danaher
  • Elan Corporation Plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • HYCOR Biomedical
  • Johnson & Johnson Inc.
  • Merck & Co. Inc.

Drivers

  • Increasing prevalence of autoimmune diseases
  • Improving regulatory framework and reimbursement policies
Speak to Analyst Request a Free Sample

Autoimmune Disease Treatment Market Overview


Autoimmune Treatment Market size is estimated to grow at a CAGR of 11.2% during the forecast period. Autoimmune diseases are kind of diseases that occur due to damage caused due to healthy body tissue by one's own immune system. Immune system disorder causes either over-activity or low immune system activity; most autoimmune diseases are chronic and have no permanent cure for them. Various external agents like bacteria, viruses, toxins, blood and tissue outside the body produce antigens which can lead to autoimmune diseases. The antibodies formed by the immune system protect the body from harmful antigens, which can affect the organs of the body.


Autoimmune diseases result in the destruction of body tissues, abnormal growth of the organ, and changes in the functions of the organ. The areas commonly get affected by autoimmune diseases are connective tissues, blood vessels, joints, muscles, and red blood cells. Celiac disease, Addison's disease, dermatomyositis, thyroid disorders, type 1 diabetes, rheumatoid arthritis, and multiple sclerosis are some of the common autoimmune diseases. A person may suffer from multiple autoimmune diseases at the same time. The commonness of autoimmune disease in women is more than that of men.


Symptoms that are related to autoimmune diseases include inflammation, fever, joint pain, fatigue, and rashes. Inflammation can lead to heat, pain, redness, and swelling of the affected body part. Diagnostic tests for autoimmune diseases include autoantibody, antinuclear antibody, comprehensive metabolic panel, urinalysis, and erythrocyte sedimentation rate. Treatment for autoimmune diseases depends on the types of disease. Treatment for autoimmune diseases includes supplements, blood transfusion, drugs, and physical therapy.


Covid-19 analysis


The global pandemic, covid-19, was a public health emergency worldwide that has affected almost every industry, and the long-term effect is predicted to impact the industrial growth during the estimated time. Due to covid, there are certain changes in the Autoimmune Disease Treatment Market like consumer behavior, breakage in the supply chain, downfall in demand, purchasing patterns, market dynamics etc.


Chief Factors Existing In The Market



  • Key Market Drivers


Various factors that drive the Market are technological advancements in the treatment sector, so that majority of the population gets interested, by providing unmet medical needs helps in the better treatment, by increasing the government assistance the Autoimmune Disease Treatment Market growth is possible, the rising commonness of co-existing disorders, improving the funding and repaying policies, are repeatedly contributing towards the growth of the autoimmune disease treatment market share.



  • Market Challenges


The safety and quality of autoimmune disease controlling therapy could be a challenge for the growth of the global autoimmune diseases treatment market. The high cost of treatment is the major drawback for the autoimmune diseases treatment market share, and the lack of infrastructure in low-income regions will hamper the disease syndrome treatment market growth rate. 



  • Market Opportunities


The Market can grow by improving the regulatory framework of the treatment. Adopting advanced technologies for better treatment could make more populations interested in implementing the treatment. Increasing the adoption rate could help in increasing the Autoimmune Disease Treatment Market value. A government funding rise for better medical facilities can enhance the market growth in many ways. The wider availability of biosimilar drugs and affordable treatment could open up opportunities for new players in the global autoimmune diseases treatment market.



  • Market Restraints


According to Autoimmune Disease Treatment Market Analysis, the market restraints are something that hampers the growth and development of the market. Lack of skilled professionals and knowledge can hamper the market growth. Lack of awareness in the population of any region can lead to unawareness of the treatment of the disease, which can be deadliest later. Poor health care facilities in some regions. These are some of the restraints of the Market.


Cumulative Evaluation Of The Market 


This disease causes the immune system to destroy its body tissue. There are over 80 different autoimmune disorders, but lupus, multiple sclerosis, IBS, type 1 diabetes, rheumatoid arthritis, psoriasis, and others are the most common forms of autoimmune disease. There are different types of drugs, such as anti-inflammatory, NSAIDs, interferons, immune suppressants, corticosteroids, and others, that are approved for the treatment of autoimmune disease.


Autoimmune Disease Treatment Market Segmentation 


The autoimmune disease treatment market is divided on the basis of disease type, diagnosis, therapeutic products, and distribution channels.


Under the basis of the disease type, the market is classified as localized and systemic. The localized segment is further classified into multiple sclerosis, inflammatory bowel disease, diabetes, and others. The systemic division is further arranged into rheumatoid arthritis, psoriasis, lupus, etc.


Under the basis of the diagnosis, the market is arranged as ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.


Under the basis of the therapeutic products, the market is arranged as drugs and therapeutic and monitoring equipment. The drugs segment is further segmented into biologics, immunosuppressants, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.


Under the basis of the distribution channel, the market is divided into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.


Autoimmune Disease Treatment Market Regional Analysis


America dominates the autoimmune disease treatment market owing to the increasing cases of autoimmune diseases and high healthcare expenditure. In 2015 as per the information given by the Centers for Disease Control and Prevention, the total healthcare expenditure in the U.S. was reported to be USD 3.2 trillion; meanwhile, hospital care was considered for a share of 32.3%.


Europe has the second rank in the autoimmune disease treatment market. It is expected that the financial support provided by the government bodies for research & development and modifications in repaying policies in healthcare is more likely to operate the European market.


Having a huge patient pool and developing healthcare technology, Asia Pacific is the fastest growing autoimmune disease treatment market. Healthcare expenditure is also found to be rising in various Asia Pacific regions. The Australian Institute of Health and Welfare suggested that the expenditure during 2014-2015 is around 3.6% higher than the total healthcare expenditure was USD 170.4 billion in 2015-2016.


The Middle East & Africa have the lowest market due to poor medical facilities and lack of technical knowledge.


Autoimmune Disease Treatment Market Competitive Outlook


The autoimmune disease treatment market outlook gives details of the competitors in the competitive landscape. The details that it provide are company overview, company financials, market potential, investment in research and development, revenue generated, new market initiatives, production sites and facilities, global presence, production capacities, company strengths and weaknesses, product width and breadth, product launch, application dominance. 


The major key players covered in the autoimmune disease treatment market report are Autoimmune Inc, LUPIN., Thermo Fisher Scientific Inc, Beckman Coulter, Inc, Chugai Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Biogen, Bayer AG, Siemens Healthcare Private Limited, Genentech, Inc, Merck Sharp & Dohme Corp, Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc and Abbott among other domestic and global players. 


Recent Market Developments



  • Celltrion Healthcare said it has successfully won a bid for Remsima, a biosimilar for AbbVie's autoimmune disease treatment Humira, in Brazil, the largest pharmaceutical market in Latin America. The company also mentioned that it had won orders from 12 provincial governmental bids.

  • The market has hired various skilled professionals, trying to put up new and advanced techniques for the growth within the autoimmune disease treatment market forecast period.


Report Overview


This report includes all the data of the market such as market overview, covid-19 analysis and how it affects the market, the key drivers, the market opportunities, the key drivers, the challenges that the market face, the market restraints, the market segmentation, the regional analysis, market outlook, the competitive landscape, report overview and recent development of the market.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   11.2% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Disease Type, Diagnosis, Therapeutic Products and Distribution
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories, Amgen Inc., Genentech Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bio-Rad, Chugai Pharmaceutical Co. Ltd., Danaher, Elan Corporation Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Johnson & Johnson Inc., Merck & Co. Inc., Siemens, Squibb Company, Thermo Fisher Scientific
  Key Market Opportunities   technological advancements and unmet medical needs
  Key Market Drivers

  • Increasing prevalence of autoimmune diseases
  • Improving regulatory framework and reimbursement policies


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Autoimmune diseases occur when the body’s immune system mistakes the body’s own tissue for foreign objects and starts attacking it.

    The market is expected to exhibit a strong 11.2% CAGR over the forecast period from 2017 to 2023.

    The growing prevalence of autoimmune diseases is the major drive for the market.

    The Americas dominate the global autoimmune disease treatment market.

    Leading players in the autoimmune disease treatment market include Abbott, Amgen, and Bayer, among others.

    Autoimmune diseases occur when the body’s immune system mistakes the body’s own tissue for foreign objects and starts attacking it.

    The market is expected to exhibit a strong 11.2% CAGR over the forecast period from 2017 to 2023.

    The growing prevalence of autoimmune diseases is the major drive for the market.

    The Americas dominate the global autoimmune disease treatment market.

    Leading players in the autoimmune disease treatment market include Abbott, Amgen, and Bayer, among others.